During the corresponding time, Phathom Pharmaceuticals Inc recorded a revenue increase by 104.43 % year on year, sequentially revenue grew by 1.25 %. While revenue at the Phathom Pharmaceuticals Inc 's corporate clients
Gastroesophageal reflux disease (GERD) is a chronic condition characterized by the backflow of stomach contents into the esophagus, causing symptoms such as heartburn, chest pain, and regurgitation. Among its various forms, Erosive GERD (EGD), which leads to inflammation and damage of the esophageal lining, poses significant treatment challenges. The introduction of innovative therapeutic options is essential for effective management of this prevalent condition. In this context, Phathom Pharmaceuticals’ VOQUEZNA (vonoprazan), a pioneering potassium-competitive acid blocker (PCAB), offers a fresh approach to treating patients with Erosive GERD and associated heartburn. Recent developments, including an exte...
Phathom Pharmaceuticals, a leading innovator in the field of gastroesophageal reflux disease (GERD) treatment, has recently launched a groundbreaking direct-to-consumer campaign for its flagship product, VOQUEZNA (vonoprazan). This campaign aims to raise awareness among millions of people suffering from Erosive GERD, encouraging them to explore the benefits of VOQUEZNA as the first and only FDA-approved potassium-competitive acid blocker (PCAB). In addition, Phathom Pharmaceuticals has also announced the commercial availability of VOQUEZNA tablets at major retail pharmacies and via BlinkRx, offering new hope for patients seeking relief from associated heartburn.Driving Awareness and Empowering PatientsThe na...
Phathom Pharmaceuticals, a leading biopharmaceutical company focused on gastrointestinal diseases, has recently announced the inclusion of VOQUEZNA (vonoprazan) tablets in the Express Scripts national formularies. This development provides a significant breakthrough in the treatment of Erosive Esophagitis, commonly known as Erosive GERD, and offers relief from associated heartburn, marking the introduction of a new class of medications for these conditions within the United States after a three-decade gap.VOQUEZNA is the first FDA-approved potassium-competitive acid blocker (PCAB), presenting a novel approach to managing Erosive GERD. By effectively reducing acid secretion in the stomach, these tablets allev...
In a significant milestone for the medical community and patients suffering from erosive gastroesophageal reflux disease (GERD), Phathom Pharmaceuticals has announced the commercial availability of VOQUEZNA (vonoprazan) Tablets. This powerful first-in-class potassium-competitive acid blocker (PCAB) has received FDA approval and is set to revolutionize the treatment landscape for GERD and provide much-needed relief from associated heartburn. As VOQUEZNA hits major retail pharmacies and the BlinkRx platform, patients can now access an innovative treatment option. The Emergence of VOQUEZNA: GERD is a chronic disorder caused by the reflux of acidic stomach contents into the esophagus, which can...
Sources:
Phathom Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Phathom Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Phathom Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %